Table 1.

Use (DDD/1000 inhabitants) in the whole population and by gender of the first 30 categories with major consumption in 2020 and comparison 2020–2019

	DDD/1000 inhabitants
	Male		Female		Total
	2020	Δ % 20–19	2020	Δ % 20–19	2020	Δ % 20–19
Antihypertensive	1120.0	− 5.4	1039.9	− 4.1	1.074.9	− 4.7
Lipid-lowering agents	348.0	− 0.7	249.5	0.2	292.5	− 0.2
Drugs for peptic ulcer and gastrooesophageal reflux disease	225.1	− 2.7	233.8	− 2.2	230.0	− 2.5
Antiplatelets	267.1	− 4.3	200.7	− 3.6	229.6	− 3.9
Antidiabetics	203.6	− 4.6	143.8	− 4.8	169.9	− 4.6
Drugs for genito-urinary disorders	307.2	− 2.5	0.9	7.5	134.5	− 2.2
Antidepressants	57.4	− 3.4	117.3	− 2.6	91.1	− 2.9
Drugs for osteoporosis	22.1	− 19.7	121.7	− 16.1	78.3	− 16.7
Drugs for asthma and COPD	90.2	− 6.2	63.3	− 5.0	75.1	− 5.6
Anticoagulants	82.6	4.7	66.7	5.2	73.6	5.0
Drugs for eye disorders	68.6	− 5.1	65.4	− 4.8	66.8	− 4.9
Drugs active on the cardiovascular system	73.7	− 9.4	57.3	− 8.8	64.4	− 9.1
Antianaemia preparations	59.1	− 3.2	61.1	− 3.6	60.2	− 3.4
Thyroid drugs	21.0	− 2.8	63.2	− 3.0	44.8	− 3.0
NSAIDs	29.9	− 13.0	42.3	− 13.2	36.9	− 13.2
Drugs for gout	48.6	− 3.9	26.5	− 3.0	36.1	− 3.5
Corticosteroids for systemic use	26.8	− 4.8	27.0	− 5.3	26.9	− 5.1
Anti-parkinsonian drugs	23.0	− 4.6	15.3	− 4.4	18.6	− 4.5
Pain therapy	14.2	− 6.2	21.8	− 5.6	18.5	− 5.8
Antibiotics	19.3	− 22.4	17.8	− 23.4	18.4	− 22.9
Oncological drugs	14.1	− 6.7	16.5	− 2.0	15.5	− 3.9
Antiepileptics	13.9	− 5.2	13.1	− 4.4	13.5	− 4.7
Antihistamines	10.3	− 0.6	13.0	− 1.3	11.8	− 1.0
Intestinal anti-inflammatory	10.3	− 5.0	8.1	− 3.8	9.1	− 4.4
Drugs for dementia	7.2	− 2.1	10.3	− 1.9	9,0	− 2,0
Antipsychotics	6.2	− 2.3	8.3	− 0.2	7,4	− 1,0
Hepatic and biliary therapy	6.1	− 1.7	6.8	− 1.1	6,5	− 1,3
Non-systemic antibiotics	5.0	− 8.6	6.6	− 6.7	5,9	− 7,4
Dermatologic drugs	6.6	− 12.8	3.0	− 13.6	4,5	− 13,0
Sexual hormones and modulators of the genital system	1.2	− 6.3	4.2	− 19.7	2,9	− 17,6